Swedish Orphan Biovitrum AB (publ) (BIT:1SOBI)
26.00
-0.64 (-2.40%)
At close: Apr 2, 2025
BIT:1SOBI Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 1,140 | 904 | 1,361 | 1,045 | 404 | Upgrade
|
Cash & Short-Term Investments | 1,140 | 904 | 1,361 | 1,045 | 404 | Upgrade
|
Cash Growth | 26.11% | -33.58% | 30.24% | 158.66% | -45.18% | Upgrade
|
Accounts Receivable | 6,976 | 6,460 | 5,582 | 3,760 | 4,060 | Upgrade
|
Other Receivables | 405 | 602 | 558 | 345 | 465 | Upgrade
|
Receivables | 7,381 | 7,062 | 6,140 | 4,105 | 4,525 | Upgrade
|
Inventory | 4,159 | 3,874 | 3,332 | 3,424 | 3,053 | Upgrade
|
Prepaid Expenses | 395 | 255 | 254 | 197 | 186 | Upgrade
|
Other Current Assets | 87 | 65 | 123 | 7 | - | Upgrade
|
Total Current Assets | 13,162 | 12,160 | 11,210 | 8,778 | 8,168 | Upgrade
|
Property, Plant & Equipment | 1,584 | 1,302 | 274 | 493 | 534 | Upgrade
|
Long-Term Investments | 36 | 37 | 64 | 145 | 132 | Upgrade
|
Goodwill | 10,456 | 9,642 | 7,007 | 6,288 | 5,873 | Upgrade
|
Other Intangible Assets | 48,306 | 49,586 | 32,259 | 31,619 | 32,372 | Upgrade
|
Long-Term Deferred Tax Assets | 1,293 | 844 | 877 | 767 | 611 | Upgrade
|
Long-Term Deferred Charges | 209 | 352 | 747 | 517 | 546 | Upgrade
|
Other Long-Term Assets | 398 | 104 | 58 | 54 | 47 | Upgrade
|
Total Assets | 75,444 | 74,027 | 52,496 | 48,661 | 48,283 | Upgrade
|
Accounts Payable | 944 | 1,024 | 1,252 | 558 | 569 | Upgrade
|
Accrued Expenses | 5,771 | 5,460 | 5,296 | 4,779 | 4,250 | Upgrade
|
Short-Term Debt | 3,926 | 3,891 | 2,067 | - | - | Upgrade
|
Current Portion of Long-Term Debt | - | 4,922 | 3,729 | 1,768 | 4,015 | Upgrade
|
Current Portion of Leases | 134 | 148 | 134 | 114 | 111 | Upgrade
|
Current Income Taxes Payable | 744 | 74 | 23 | 40 | 518 | Upgrade
|
Other Current Liabilities | 1,081 | 3,576 | 2,356 | 1,502 | 980 | Upgrade
|
Total Current Liabilities | 12,600 | 19,095 | 14,857 | 8,761 | 10,443 | Upgrade
|
Long-Term Debt | 12,407 | 11,356 | 2,971 | 8,777 | 10,137 | Upgrade
|
Long-Term Leases | 268 | 168 | 200 | 247 | 308 | Upgrade
|
Long-Term Deferred Tax Liabilities | 6,702 | 6,680 | 3,797 | 3,605 | 3,464 | Upgrade
|
Other Long-Term Liabilities | 2,896 | 2,651 | 4,059 | 3,920 | 3,581 | Upgrade
|
Total Liabilities | 35,149 | 40,160 | 25,971 | 25,458 | 28,077 | Upgrade
|
Common Stock | 195 | 194 | 170 | 169 | 167 | Upgrade
|
Additional Paid-In Capital | 17,186 | 16,552 | 10,211 | 9,945 | 9,816 | Upgrade
|
Retained Earnings | 21,924 | 18,055 | 15,793 | 13,155 | 10,477 | Upgrade
|
Comprehensive Income & Other | 981 | -934 | 351 | -66 | -254 | Upgrade
|
Total Common Equity | 40,286 | 33,867 | 26,525 | 23,203 | 20,206 | Upgrade
|
Minority Interest | 9 | - | - | - | - | Upgrade
|
Shareholders' Equity | 40,295 | 33,867 | 26,525 | 23,203 | 20,206 | Upgrade
|
Total Liabilities & Equity | 75,444 | 74,027 | 52,496 | 48,661 | 48,283 | Upgrade
|
Total Debt | 16,735 | 20,485 | 9,101 | 10,906 | 14,571 | Upgrade
|
Net Cash (Debt) | -15,595 | -19,581 | -7,740 | -9,861 | -14,167 | Upgrade
|
Net Cash Per Share | -45.13 | -60.07 | -25.93 | -33.22 | -47.60 | Upgrade
|
Filing Date Shares Outstanding | 343.44 | 339.76 | 296.02 | 295.16 | 294.9 | Upgrade
|
Total Common Shares Outstanding | 343.44 | 339.76 | 296.02 | 295.16 | 294.9 | Upgrade
|
Working Capital | 562 | -6,935 | -3,647 | 17 | -2,275 | Upgrade
|
Book Value Per Share | 117.30 | 99.68 | 89.61 | 78.61 | 68.52 | Upgrade
|
Tangible Book Value | -18,476 | -25,361 | -12,741 | -14,704 | -18,039 | Upgrade
|
Tangible Book Value Per Share | -53.80 | -74.64 | -43.04 | -49.82 | -61.17 | Upgrade
|
Machinery | 696 | 666 | 648 | 673 | 646 | Upgrade
|
Construction In Progress | 1,161 | 1,063 | 8 | 23 | 9 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.